88 studies found for:    "spinocerebellar degenerations" OR "marinesco-sjogren syndrome"
Show Display Options
Rank Status Study
1 Recruiting Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias
Conditions: Spinocerebellar Ataxia Type 1;   Spinocerebellar Ataxia Type 2;   Spinocerebellar Ataxia Type 3;   Spinocerebellar Ataxia Type 6
Intervention: Genetic: All Participants
2 Unknown  Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations
Conditions: Spinocerebellar Ataxias;   Spastic Paraplegias
Intervention:
3 Completed
Has Results
Dalfampridine and Gait in Spinocerebellar Ataxias
Conditions: Spinocerebellar Ataxias Type 1;   Spinocerebellar Ataxias Type 2;   Spinocerebellar Ataxias Type 3;   Spinocerebellar Ataxias Type 6
Interventions: Drug: Dalfampridine;   Drug: Placebo
4 Recruiting A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Condition: Spinocerebellar Degeneration
Interventions: Drug: KPS-0373, High dose;   Drug: KPS-0373, Low dose
5 Recruiting An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Condition: Spinocerebellar Degeneration
Interventions: Drug: KPS-0373, High dose;   Drug: KPS-0373, Low dose
6 Recruiting A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Condition: Spinocerebellar Degeneration
Interventions: Drug: KPS-0373, High dose;   Drug: KPS-0373, Low dose;   Drug: Placebo
7 Recruiting A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Condition: Spinocerebellar Degeneration
Interventions: Drug: KPS-0373, High dose;   Drug: KPS-0373, Low dose
8 Completed A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Condition: Spinocerebellar Degeneration
Interventions: Drug: KPS-0373;   Drug: Placebo
9 Completed Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Condition: Spinocerebellar Degeneration
Intervention: Drug: KPS-0373
10 Recruiting Transcranial Magnetic Stimulation in Spino-Cerebellar Ataxia
Condition: Spinocerebellar Ataxia
Intervention: Device: Transcranial Magnetic Stimulation
11 Completed Lithium Treatment for Patients With Spinocerebellar Ataxia Type I
Condition: Spinocerebellar Ataxia Type I
Intervention: Drug: Lithium Carbonate
12 Completed Measuring Neurological Impairment and Functional Visual Assessment In Spinocerebellar Ataxias
Condition: Spinocerebellar Ataxia
Intervention:
13 Completed Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3
Conditions: Spinocerebellar Ataxia Type 3;   Machado Joseph Disease
Interventions: Drug: Lithium Carbonate;   Drug: Placebo
14 Completed Parkinsonism in Spinocerebellar Ataxia Type 6
Condition: Spinocerebellar Ataxia Type 6
Intervention:
15 Not yet recruiting Functional and Structural Imaging and Motor Control in Spinocerebellar Ataxia
Condition: Spinocerebellar Ataxia
Interventions: Behavioral: Error-reduction;   Behavioral: International Cooperative Ataxia Rating Scale;   Behavioral: Scale for the Assessment and Rating of Ataxia
16 Completed Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar Ataxia
Condition: Spinocerebellar Ataxia
Intervention: Biological: IVIG
17 Recruiting An Open-label Trial of Intravenous Immune Globulin (IVIG)in Treating Spinocerebellar Ataxias
Condition: Spinocerebellar Ataxias
Intervention: Drug: Intravenous Immune Globulin (IVIG)
18 Completed Safety and Tolerability of Lithium in Spinocerebellar Ataxia 2 (SCA2)
Condition: SPINOCEREBELLAR ATAXIA 2
Intervention: Drug: LITHIUM CARBONATE
19 Completed Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3
Condition: Spinocerebellar Ataxia Type 3
Interventions: Drug: varenicline;   Drug: placebo
20 Active, not recruiting Biomarkers in Autosomal Dominant Cerebellar Ataxia
Conditions: Spinocerebellar Ataxia Type 1;   Spinocerebellar Ataxia Type 2;   Spinocerebellar Ataxia, Autosomal Recessive 3;   Episodic Ataxia, Type 7
Intervention: Other: metabolic and imaging biomarkers in SCA1,2,3 and 7 patients

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years